Pathologicl scar
Conditions
Interventions
Part I: Normal group, hypertrophic scar group, keloid group:None
Part Two: Interference Group:None
Part III: Pathological scar group:Glucocorticoid injection therapy
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Part I: Age 18-60 years old. Part II: The second part: rheumatism, diabetes, infection, inflammation, cancer, malignant fibrosarcoma protuberans, cardiovascular disease, hepatitis, primary nephrotic syndrome, etc. 18-60 years old. Part III: patients with pathological scar; 18-60 years old.
Exclusion criteria
Exclusion criteria: Part I:Patients with oxidative stress-related diseases such as rheumatism, diabetes, cancer, cardiovascular disease, and infectious diseases; The scar had been treated within the past half a year. Scar surface ulceration, infection, etc. The history of trauma and surgery in the past six months; During pregnancy or lactation; Inability to accept the risks of research or unwillingness to accept research; Patients who are unable to give oral and written informed consent, patients who are unable to communicate normally. Part II: Patients with a history of pathological scar (hypertrophic scar or keloid); The history of trauma and surgery in the past six months; During pregnancy or lactation; Inability to accept the risks of research or unwillingness to accept research; Patients who are unable to give oral and written informed consent, patients who are unable to communicate normally. Part III: Patients with oxidative stress-related diseases such as rheumatism, diabetes, cancer, cardiovascular disease, and infectious diseases; A history of scar treatment in the past half a year; Surface ulceration and infection of scar area; Other patients who are not suitable for injection therapy; The history of trauma and surgery in the past six months; During pregnancy or lactation; Inability to accept the risks of research or unwillingness to accept research; Patients who are unable to give oral and written informed consent, patients who are unable to communicate normally.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum TXNIP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vancouver scar score;Serum TGF-ß; | — |
Countries
China
Contacts
Public ContactZhai Xiaomei
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed